Source: Benzinga

BioLineRx: Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet

Followers on Owler

Annual Revenue

$25-100M

Employees

25-100

CEO

Philip Serlin

CEO Approval Rating

90/100

BioLineRx is an Israel-based clinical-stage biopharmaceutical company that researches and develops novel therapeutics for the treatment of cancer.